Table 1.
Shantha Timeline
| Year | Milestone |
|---|---|
| 1992 | Dr. Varaprasad attends immunization conference in Geneva; Hep-B idea forms |
| 1993 | Shantha Biotechnics is born, staff works out of Osmania University |
| 1994 | Shantha Biotechnics moves to Centre for Cellular and Molecular Biology |
| 1995 | Oman invests $1.2 million in equity; Shantha moves into own facility |
| 1997 | Shantha's Hepatitis B vaccine, Shanvac-B, launched (first recombinant health product in India) |
| 1998 | Shantha sells 22 million doses of Shanvac-B this year, far exceeding expectations |
| 1999 | Comparative study proving the high quality of Shanvac-B published in Vaccine |
| 2000 | Morgan Stanley and State Bank of Indian Mutual Fund invest $10 million in equity |
| 2002 | Shantha introduces first bio-therapeutic product, Interferon α 2b, onto the market Shantha receives WHO pre-qualification for Shanvac-B |
| 2005 | Shantha introduces first combination vaccine onto market - Shantetra (diphtheria, pertussis, tetanus, hepatitis B) |
| 2007 | Merieux Alliance picks up 60% stake in Shantha, which it later expands to 80% |
| 2009 | Shantha wins a $340 M USD contract from UNICEF for pentavalent vaccines |
| Sanofi-Aventis acquires an 80% controlling stake valuing the firm at $784 M USD | |